SNOA · XBRL financial data
Sonoma Pharmaceuticals financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (SNOA's year ends in late March)
| In thousands of dollars | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | Mar 31, 2025 | †Mar 31, 2026 |
|---|---|---|---|---|---|---|
| Revenue | 18,629 | 12,628 | 13,272 | 12,735 | 14,288 | 19,529 |
| Revenue from contracts with customers | 18,629 | 12,628 | 13,272 | 12,735 | 14,288 | 19,529 |
| Cost of revenue | — | — | — | — | 8,823 | 12,114 |
| Cost of goods and services sold | 12,070 | 8,635 | 8,795 | 7,990 | 8,823 | — |
| Gross profit | 6,559 | 3,993 | 4,477 | 4,745 | 5,465 | 7,415 |
| Research and development | 555 | 125 | 207 | 1,871 | 1,814 | 2,271 |
| Selling, general and administrative | 9,453 | 9,755 | 8,840 | 7,575 | 7,361 | 7,605 |
| Total operating expenses | 10,008 | 9,880 | 9,047 | 9,446 | 9,175 | 9,876 |
| Other operating income (expense) | (594) | (394) | (631) | (330) | 803 | (958) |
| Operating income (loss) | (3,449) | (5,887) | (4,570) | (4,701) | (3,710) | (2,461) |
| Interest income | 16 | — | — | — | — | — |
| Interest expense | 12 | — | — | — | — | — |
| Income tax expense (benefit) | 713 | (332) | (33) | (196) | 550 | (244) |
| Net income (loss) | (3,950) | (5,086) | (5,151) | (4,835) | (3,457) | (3,175) |
| Earnings per share, basic USD per share | — | (1.92) | (1.52) | (0.53) | (2.79) | (1.89) |
| Earnings per share, diluted USD per share | — | (1.92) | (1.52) | (0.53) | (2.79) | (1.89) |
| Weighted average shares, basic thousands of shares | — | 3 | 3 | 9,090 | 1,241 | 1,684 |
| Weighted average shares, diluted thousands of shares | — | 3 | 3 | 9,090 | 1,241 | 1,684 |
- † Share count changed about 3x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (SNOA's year ends in late March)
| In thousands of dollars | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | Mar 31, 2025 | †Mar 31, 2026 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4,220 | 7,396 | 3,820 | 3,128 | 5,374 | 2,399 |
| Accounts receivable | 2,806 | 2,407 | 2,572 | 2,898 | 2,232 | 2,527 |
| Inventory | 2,530 | 2,663 | 2,858 | 2,719 | 2,915 | 3,651 |
| Prepaid and other current assets | 3,218 | 3,746 | 4,308 | 3,541 | 1,915 | 3,436 |
| Total current assets | 12,983 | 16,430 | 13,798 | 12,548 | 12,648 | 12,100 |
| Property and equipment, net | 360 | 320 | 488 | 365 | 225 | 310 |
| Right-of-use asset | 769 | 559 | 418 | 286 | 84 | 602 |
| Total assets | 14,987 | 18,845 | 16,231 | 14,740 | 13,693 | 13,960 |
| Accounts payable | 1,769 | 1,641 | 841 | 607 | 953 | 1,923 |
| Current portion of long-term debt | 596 | — | — | — | — | — |
| Total current liabilities | 4,078 | 5,819 | 3,717 | 3,719 | 4,096 | 4,832 |
| Long-term debt | 1,310 | 0 | — | — | — | — |
| Lease liability, non-current | 529 | 309 | 162 | 87 | 27 | 469 |
| Total liabilities | 9,624 | 10,148 | 8,254 | 8,603 | 9,282 | 10,865 |
| Accumulated deficit | (179,277) | (184,363) | (189,514) | (194,349) | (197,806) | (200,981) |
| Total stockholders' equity | 5,363 | 8,697 | 7,977 | 6,137 | 4,411 | 3,095 |
| Total liabilities and equity | 14,987 | 18,845 | 16,231 | 14,740 | 13,693 | 13,960 |
| Common shares outstanding (cover page) thousands of shares | 2,091 | 3,101 | 4,942 | 18,774 | 1,643 | 4,786 |
- † Share count changed about 3x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (SNOA's year ends in late March)
| In thousands of dollars | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | Mar 31, 2025 | †Mar 31, 2026 |
|---|---|---|---|---|---|---|
| Net income (loss) | (3,950) | (5,086) | (5,151) | (4,835) | (3,457) | (3,175) |
| Stock-based compensation | 371 | 382 | 669 | 516 | 224 | 255 |
| Depreciation and amortization | 227 | 186 | 125 | 176 | — | — |
| Net cash from operating activities | (3,378) | (4,248) | (6,152) | (2,398) | (88) | (3,933) |
| Purchases of property and equipment | 179 | 137 | 269 | 17 | 80 | 192 |
| Net cash from investing activities | 388 | (99) | (258) | (2) | (80) | (192) |
| Proceeds from issuing common stock | 0 | 7,554 | 2,868 | 1,784 | 3,079 | 427 |
| Repayments of long-term debt | 481 | 30 | 774 | — | — | — |
| Net cash from financing activities | 3,308 | 7,396 | 2,489 | 1,676 | 3,030 | 477 |
| Net change in cash | 529 | 3,176 | (3,576) | (692) | 2,246 | (2,975) |
- † Share count changed about 3x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Sonoma Pharmaceuticals | 5,338 | 6,406 | (649) | 4.8M | 8.2 quarters | 10-QJun 30, 2026 |
| Autonomix Medical | 3,460 | 0 | (3,544) | 971,043 | 1.0 quarters | 10-QJun 30, 2026 |
| Odyssey Health | 122 | not reported | (160)* | 110.2M | 0.8 quarters | 10-KJul 31, 2026 |
| Family Office of America | 637 | 533 | 149* | 30.8M | — | 10-QJun 30, 2026 |
| Adm Tronics Unlimited | 223 | not reported | (33) | 67.6M | 6.8 quarters | 10-QJun 30, 2026 |
| Aethlon Medical | 4,934 | not reported | (1,897) | 711,136 | 2.6 quarters | 10-QJun 30, 2026 |
| Bone Biologics | 6,088 | not reported | (532)* | 3.4M | 9.8 quarters | 10-QSep 30, 2026 |
| SeaStar Medical Holding | 6,959 | 615 | (2,994)* | 4.4M | 2.3 quarters | 10-QJun 30, 2026 |
| ENvue Medical | 1,084 | 239 | (2,691)* | 11.1M | 0.4 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.